Development of Paediatric Medicines: Concepts and PrinciplesROSE, Klaus; PASQUA, Oscar Della.Handbook of experimental pharmacology. 2011, Vol 205, pp 111-124, issn 0171-2004, 14 p.Article

Cannabinoid system in the skin - a possible target for future therapies in dermatologyKUPCZYK, Piotr; REICH, Adam; SZEPIETOWSKI, Jacek C et al.Experimental dermatology. 2009, Vol 18, Num 8, pp 669-679, issn 0906-6705, 11 p.Article

Quantitative Disease, Drug, and Trial ModelsGOBBURU, Jogarao V. S; LESKO, Lawrence J.Annual review of pharmacology and toxicology (Print). 2009, Vol 49, pp 291-301, issn 0362-1642, 11 p.Article

Scaling of pharmacokinetics across paediatric populations: the lack of interpolative power of allometric modelsCELLA, Massimo; KNIBBE, Catherijne; DE WILDT, Saskia N et al.British journal of clinical pharmacology. 2012, Vol 74, Num 3, pp 525-535, issn 0306-5251, 11 p.Article

Fixing the paradigm for biopharmaceutical R&D : Where to start?MILNE, Christopher-Paul.International journal of biotechnology. 2008, Vol 10, Num 5, pp 404-415, issn 0963-6048, 12 p.Article

Better medicines for children : where are we now, and where do we want to be?ROSE, Klaus.British journal of clinical pharmacology. 2005, Vol 59, Num 6, pp 657-659, issn 0306-5251, 3 p.Conference Paper

NON-CLINICAL SAFETY IN DRUG DEVELOPMENTLOGET, Olivier Marcel Louis.Bulletin de l'Académie vétérinaire de France. 2008, Vol 161, Num 1, pp 61-69, issn 0001-4192, 9 p.Article

The Impact of Ethnomycology on Modern Pharmacy = L'impact de l'ethnomycologie sur la pharmacie moderneLINDEQUIST, Ulrike.Curare. 2011, Vol 34, Num 1-2, pp 118-123, issn 0344-8622, 6 p.Conference Paper

Food and drug administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim : Negative symptomsLAUGHREN, Thomas; LEVIN, Robert.Schizophrenia bulletin. 2006, Vol 32, Num 2, pp 220-222, issn 0586-7614, 3 p.Article

Adaptive trials in paediatric development: dealing with heterogeneity and uncertainty in pharmacokinetic differences in childrenCELLA, Massimo; DANHOF, Meindert; DELLA PASQUA, Oscar et al.British journal of clinical pharmacology. 2012, Vol 74, Num 2, pp 346-353, issn 0306-5251, 8 p.Article

Developing MicroRNA Therapeutics : MicroRNas in the Cardiovascular SystemVAN ROOIJ, Eva; PURCELL, Angela L; LEVIN, Arthur A et al.Circulation research. 2012, Vol 110, Num 3, pp 496-507, issn 0009-7330, 12 p.Article

Optimal dose finding for novel antimalarial combination therapyDUPARC, S; LANZA, C; UBBEN, D et al.TM & IH. Tropical medicine & international health. 2012, Vol 17, Num 4, pp 409-413, issn 1360-2276, 5 p.Article

A current practice for predicting ocular toxicity of systemically delivered drugsSOMPS, Chris J; GREENE, Nigel; RENDER, James A et al.Cutaneous and ocular toxicology (Print). 2009, Vol 28, Num 1, pp 1-18, issn 1556-9527, 18 p.Article

The silent treatment : siRNAs as small molecule drugsDYKXHOORN, D. M; PALLISER, D; LIEBERMAN, J et al.Gene therapy (Basingstoke). 2006, Vol 13, Num 6, pp 541-552, issn 0969-7128, 12 p.Article

Overview of the clinical efficacy of investigational anticancer drugsNYGREN, P; LARSSON, R.Journal of internal medicine. 2003, Vol 253, Num 1, pp 46-75, issn 0954-6820, 30 p.Article

Biotech and pharma: State of the relationship in the new millenniumCUNNINGHAM, Brian C.Drug development research. 2002, Vol 57, Num 2, pp 97-102, issn 0272-4391, 6 p.Article

Relationship between drug lag and factors associated with clinical trials in JapanOHWAKI, K; NAKABAYASHI, T.Journal of clinical pharmacy and therapeutics (Print). 2014, Vol 39, Num 6, pp 649-652, issn 0269-4727, 4 p.Article

How modeling and simulation have enhanced decision making in new drug developmentMILLER, Raymond; EWY, Wayne; LI, Cheryl S. W et al.Journal of pharmacokinetics and pharmacodynamics (Print). 2005, Vol 32, Num 2, pp 185-197, issn 1567-567X, 13 p.Article

Resolution of cellular physiology by genomic expression signature analysis: Bridging the content gap between in vitro and in vivo drug developmentGUNTHER, Erik C; GERWIEN, Robert W.Drug development research. 2004, Vol 62, Num 2, pp 119-123, issn 0272-4391, 5 p.Article

Quantitative real time polymerase chain reaction in drug developmentGOODSAID, Federico.Drug development research. 2004, Vol 62, Num 2, pp 151-158, issn 0272-4391, 8 p.Article

A Human Approach to Drug Development: Opportunities and LimitationsCOLEMAN, Robert A.ATLA. Alternatives to laboratory animals. 2010, Vol 38, pp 21-25, issn 0261-1929, 5 p., SUP1Conference Paper

Targeting epigenetic abnormalities with histone deacetylase inhibitorsCONLEY, Barbara A; WRIGHT, John J; KUMMAR, Shivaani et al.Cancer. 2006, Vol 107, Num 4, pp 832-840, issn 0008-543X, 9 p.Article

The teaching of drug development to medical students : collaboration between the pharmaceutical industry and medical schoolSTANLEY, A. G; JACKSON, D; BARNETT, D. B et al.British journal of clinical pharmacology. 2005, Vol 59, Num 4, pp 464-474, issn 0306-5251, 11 p.Article

Pharmacogenomic approaches in antidiabetic drug developmentROSMOND, Roland.Drug development research. 2004, Vol 62, Num 3, pp 207-212, issn 0272-4391, 6 p.Article

Collaborative National ALS Study Group. Patient orientated research and clinical trialsBRADLEY, Walter G.Journal of the neurological sciences. 2006, Vol 242, Num 1-2, pp 71-74, issn 0022-510X, 4 p.Article